Derfuss T - Search Results

1

Defining distinct features of anti-MOG antibody associated central nervous system demyelination.

Weber MS, Derfuss T, Metz I, Brück W. Weber MS, et al. Among authors: derfuss t. Ther Adv Neurol Disord. 2018 Mar 29;11:1756286418762083. doi: 10.1177/1756286418762083. eCollection 2018. Ther Adv Neurol Disord. 2018. PMID: 29623106 Free PMC article. Review.

2

The ACROSS study: Long-term efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis.

Derfuss T, Sastre-Garriga J, Montalban X, Rodegher M, Wuerfel J, Gaetano L, Tomic D, Azmon A, Wolf C, Kappos L. Derfuss T, et al. Mult Scler J Exp Transl Clin. 2020 Mar 30;6(1):2055217320907951. doi: 10.1177/2055217320907951. eCollection 2020 Jan-Mar. Mult Scler J Exp Transl Clin. 2020. PMID: 32284874 Free PMC article.

3

Identifying autoantigens in demyelinating diseases: valuable clues to diagnosis and treatment?

Derfuss T, Meinl E. Derfuss T, et al. Curr Opin Neurol. 2012 Jun;25(3):231-8. doi: 10.1097/WCO.0b013e3283533a64. Curr Opin Neurol. 2012. PMID: 22487571 Review.

4

Aquaporin-4 antibody negative recurrent isolated optic neuritis: clinical evidence for disease heterogeneity.

Waschbisch A, Atiya M, Schaub C, Derfuss T, Schwab S, Lee DH, Müller M, Linker RA. Waschbisch A, et al. Among authors: derfuss t. J Neurol Sci. 2013 Aug 15;331(1-2):72-5. doi: 10.1016/j.jns.2013.05.012. Epub 2013 Jun 2. J Neurol Sci. 2013. PMID: 23735776

5

Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype.

Pröbstel AK, Rudolf G, Dornmair K, Collongues N, Chanson JB, Sanderson NS, Lindberg RL, Kappos L, de Seze J, Derfuss T. Pröbstel AK, et al. Among authors: derfuss t. J Neuroinflammation. 2015 Mar 8;12:46. doi: 10.1186/s12974-015-0256-1. J Neuroinflammation. 2015. PMID: 25889963 Free PMC article.

6

Disease activity return after natalizumab cessation in multiple sclerosis.

Rasenack M, Derfuss T. Rasenack M, et al. Among authors: derfuss t. Expert Rev Neurother. 2016 May;16(5):587-94. doi: 10.1586/14737175.2016.1168295. Epub 2016 Apr 6. Expert Rev Neurother. 2016. PMID: 26988737 Review.

7

Promising Oral Compounds for the Treatment of Multiple Sclerosis: A Glance into the Future.

Décard BF, Derfuss T. Décard BF, et al. Among authors: derfuss t. Semin Neurol. 2016 Apr;36(2):128-39. doi: 10.1055/s-0036-1580720. Epub 2016 Apr 26. Semin Neurol. 2016. PMID: 27116719 Review.

8

Expression of the Antioxidative Enzyme Peroxiredoxin 2 in Multiple Sclerosis Lesions in Relation to Inflammation.

Voigt D, Scheidt U, Derfuss T, Brück W, Junker A. Voigt D, et al. Among authors: derfuss t. Int J Mol Sci. 2017 Apr 4;18(4):760. doi: 10.3390/ijms18040760. Int J Mol Sci. 2017. PMID: 28375164 Free PMC article.

9

Anti-Myelin Oligodendrocyte Glycoprotein Antibody-Associated Central Nervous System Demyelination-A Novel Disease Entity?

Weber MS, Derfuss T, Brück W. Weber MS, et al. Among authors: derfuss t. JAMA Neurol. 2018 Aug 1;75(8):909-910. doi: 10.1001/jamaneurol.2018.1055. JAMA Neurol. 2018. PMID: 29913011 No abstract available.

10

Magnetic resonance imaging in immune-mediated myelopathies.

Wendebourg MJ, Nagy S, Derfuss T, Parmar K, Schlaeger R. Wendebourg MJ, et al. Among authors: derfuss t. J Neurol. 2020 May;267(5):1233-1244. doi: 10.1007/s00415-019-09206-2. Epub 2019 Jan 29. J Neurol. 2020. PMID: 30694379 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results